Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients

  • Dumitru I
  • Dumitru E
  • Tuta L
  • et al.
N/ACitations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

The objectives of the study were to determine the efficacy of pegylated interferon alfa 2 b (PegINF) and ribavirin (RBV) treatment in co-infected HIV / HCV patients, to identify predictive factors associated with sustained viral response (SVR) in these patients. Out of the 956 HIV infected patients, 38 were HCVAb (4%) positive, 14 of which had undetectable HCV RNA, only 6 patients met the inclusion criteria. Screening failure was due to: liver cirrhosis Child Pugh B / C, hepatocellular carcinoma, pulmonary TB, thyroid dysfunction, CD4 <200 cells3, detectable HIV RNA and depressive syndrome. We initiated PegINF and RBV therapy for 48 weeks. SVR was achieved in 16.6% of cases (only one patient) and correlated with HCV RNA level, CD4 count, duration of HIV infection, CDC classification and liver fibrosis. In conclusion, our study group has a low prevalence of HIV / HCV co-infection (2.6%) with a large number of patients HCVAb positive but undetectable HCV RNA. Positive predictive factors for SVR were: low levels of HCV RNA, small duration of HIV infection, high levels of CD4, B1/B2 (CDC classification) and low degree of fibrosis.

Cite

CITATION STYLE

APA

Dumitru, I. M., Dumitru, E., Tuta, L. A., & Rugina, S. (2017). Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients. ARS Medica Tomitana, 23(1), 47–52. https://doi.org/10.1515/arsm-2017-0009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free